Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Ertugliflozin & Type 2 diabetes (T2D), the US FDA approved ertugliflozin as an oral SGLT2 inhibitor for adults with type 2 diabetes, as an adjunct to diet and exercise to improve glycemic control.
acpd-20180112_7
The European Medicines Agency (EMA) has granted marketing authorization for ertugliflozin for the treatment of adults with type 2 diabetes. This appr…